Atyr Pharma (ATYR) Stock News
$ATYR · NASDAQ · 3 stories in 30 daysBORSA has published 3 stories on Atyr Pharma (ATYR) in the past 30 days. BORSA’s news read on ATYR is bearish at 35/100, unchanged over 24 hours, based on 3 company events over the past 7 days. ATYR last closed at $4.94 on Oct 30, down 25.20% over five sessions and down 58.01% over the past month. Atyr Pharma’s next earnings report is scheduled for Thursday, Nov 5.
The wire on $ATYR
newest first · updated · direct subject stories onlyaTyr Pharma (ATYR) Resumes Trading After Halt.
bearish 35 · impact 20aTyr Pharma (ATYR) published Phase 3 EFZO-FIT results in The Lancet Respiratory Medicine. The trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint of steroid dose reduction at week 48. It improved multiple patient-reported outcomes, maintained lung function, and was well-tolerated. The company is advancing a new Phase 3 study in pulmonary sarcoidosis and a Phase 2 study in scleroderma-related ILD.
bearish 35 · impact 40